Health & Environmental Research Online (HERO)


Print Feedback Export to File
7439559 
Journal Article 
The immuno-oncological challenge of COVID-19 
Derosa, L; Melenotte, C; Griscelli, F; Gachot, B; Marabelle, A; Kroemer, G; Zitvogel, L; , 
2020 
1 
10 
946-964 
Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.